POSB105 Budget Impact Analysis of Introduction of Subcutaneous Infliximab in France from a Payer Perspective von Pradie, M, Hadjadj, C, Petiteau Moreau, F

Volltext

P42 Budget Impact Analysis of Eculizumab Biosimilar for Treatment of Paroxysmal Nocturnal Hemoglobinuria from Public Hospital Perspective in 2023 von Robin, P., De Coucy, A., Hadjadj, C., Moreau F, Petiteau

Volltext

PBI16 COST ANALYSIS OF TWO TREATMENTS BY INFLIXIMAB (ORIGINATOR AND BIOSIMILAR) FOR PATIENTS WITH RHUMATOÏD ARTHRITIS (RA) OR INFLAMMATORY BOWEL DISEASE (IBD) IN A GROUP OF FRENCH... von Petiteau Moreau, F., Hadjadj, C., Feuillerat, M.

Volltext

PUK12 - Cost Minimization Analysis Of Immunosuppressive Treatment On Kidney Transplant Patients von Petiteau Moreau, F, Desbouis, C, Hadjadj, C, Klett, A, Hauville, C, Lucats, L, Merville, P, Etienne, I, Tilleul, P

Volltext

Cost Minimization Analysis Of Immunosuppressive Treatment On Kidney Transplant Patients von Petiteau Moreau, F, Desbouis, C, Hadjadj, C, Klett, A, Hauville, C, Lucats, L, Merville, P, Etienne, I, Tilleul, P

Volltext